Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial

被引:133
|
作者
Bousquet, J [1 ]
Lund, VJ
van Cauwenberge, P
Bremard-Oury, C
Mounedji, N
Stevens, MT
El-Akkad, T
机构
[1] Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France
[2] Ghent Univ Hosp, B-9000 Ghent, Belgium
[3] UCL, Sch Med, London W1N 8AA, England
[4] Lab Aventis, Paris, France
[5] EmStat Ltd, Leicester, Leics, England
[6] Aventis Pharma, Bridgewater, NJ USA
关键词
histamine H-1 antagonists; intranasal administration; practice guidelines; quality of life; seasonal allergic rhinitis;
D O I
10.1034/j.1398-9995.2003.00076.x
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Allergic rhinitis is a common disease altering quality of life. Its treatment is well established and guidelines have been proposed. However, their efficacy has never been tested. The aim of the study was to validate the guidelines of the International Consensus on Rhinitis in the treatment of seasonal allergic rhinitis. Methods: A multicenter, multinational, open label, parallel, randomized study compared two therapeutic strategies in seasonal allergic rhinitis during a 3-week treatment. General practitioners were randomized into two groups. In the first group of 224 patients, doctors followed guidelines from the International Consensus on Rhinitis. Depending on the severity of nasal and ocular symptoms defined using visual analogue scales, patients received ebastine (an oral antihistamine), triamcinolone acetonide (a topical corticosteroid) and/or ophthalmic nedocromil sodium (a topical ocular cromone). In the second group of 241 patients, general practitioners had a free choice of treatment. The primary efficacy end points were quality of life measured using the standardized rhinoconjunctivitis quality of life questionnaire (RQLQ) and the symptom-medication scores assessed daily with an electronic dairy system. Results: Adjusted mean total symptom scores over 21 days were 4.93 in the guidelines strategy group compared with 7.48 in the free-choice treatment group (P = 0.0001). Mean total scores in the RQLQ decreased by 2.19 in the guidelines group compared with a decrease of 1.79 in the free-choice treatment group (P = 0.0001). At 21 days, the least square mean difference in improvement in overall scores for RQLQ in the guidelines group compared with the free-choice treatment group was 0.53, which was greater than the minimal important difference. Conclusions: Patients with seasonal allergic rhinitis often present severe symptoms which are not well recognized or controlled by physicians using their own criteria of severity and treatment. Using a simple method for the evaluation of the severity and a simple therapeutic scheme based on International Guidelines, patients with seasonal allergic rhinitis presented a significant improvement by comparison with those receiving a non-standardized treatment.
引用
收藏
页码:733 / 741
页数:9
相关论文
共 50 条
  • [1] Implementation of Guidelines for Allergic Rhinitis in Specialist Practices Randomized Pragmatic Controlled Trial
    Bousquet, Jean
    Bodez, Thierry
    Gehano, Pierre
    Klossek, Jean Michel
    Liard, Francois
    Neukirch, Francoise
    Le Gal, Martine
    Janin, Nicole
    Allaf, Bashar
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2009, 150 (01) : 75 - 82
  • [2] Acupuncture for seasonal allergic rhinitis: a randomized controlled trial
    Xue, Charlie Changli
    Zhang, Anthony Lin
    Zhang, Claire Shuiqing
    DaCosta, Cliff
    Story, David F.
    Thien, Frank C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 115 (04) : 317 - +
  • [3] Acupressure in patients with seasonal allergic rhinitis: a randomized controlled exploratory trial
    Lukas Israel
    Gabriele Rotter
    Ulrike Förster-Ruhrmann
    Josef Hummelsberger
    Rainer Nögel
    Andreas Michalsen
    Tatjana Tissen-Diabaté
    Sylvia Binting
    Thomas Reinhold
    Miriam Ortiz
    Benno Brinkhaus
    Chinese Medicine, 16
  • [4] Effect of omalizumab on symptoms of seasonal allergic rhinitis - A randomized controlled trial
    Casale, TB
    Condemi, J
    LaForce, C
    Nayak, A
    Rowe, M
    Watrous, M
    McAlary, M
    Fowler-Taylor, A
    Racine, M
    Gupta, N
    Fick, R
    Della Cioppa, G
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (23): : 2956 - 2967
  • [5] Acupressure in patients with seasonal allergic rhinitis: a randomized controlled exploratory trial
    Israel, Lukas
    Rotter, Gabriele
    Foerster-Ruhrmann, Ulrike
    Hummelsberger, Josef
    Noegel, Rainer
    Michalsen, Andreas
    Tissen-Diabate, Tatjana
    Binting, Sylvia
    Reinhold, Thomas
    Ortiz, Miriam
    Brinkhaus, Benno
    CHINESE MEDICINE, 2021, 16 (01)
  • [6] Effect of acupuncture in the treatment of seasonal allergic rhinitis: A randomized controlled clinical trial
    Xue, CCL
    English, R
    Zhang, JJS
    Da Costa, C
    Li, CG
    AMERICAN JOURNAL OF CHINESE MEDICINE, 2002, 30 (01): : 1 - 11
  • [7] Acupuncture in Patients With Seasonal Allergic Rhinitis A Randomized Trial
    Brinkhaus, Benno
    Ortiz, Miriam
    Witt, Claudia M.
    Roll, Stephanie
    Linde, Klaus
    Pfab, Florian
    Niggemann, Bodo
    Hummelsberger, Josef
    Treszl, Andras
    Ring, Johannes
    Zuberbier, Torsten
    Wegscheider, Karl
    Willich, Stefan N.
    ANNALS OF INTERNAL MEDICINE, 2013, 158 (04) : 225 - 234
  • [8] Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial
    Lou, Hongfei
    Huang, Yanran
    Ouyang, Yuhui
    Zhang, Yuan
    Xi, Lin
    Chu, Xiaohan
    Wang, Yang
    Wang, Chengshuo
    Zhang, Luo
    ALLERGY, 2020, 75 (08) : 2026 - 2036
  • [9] Treatment for seasonal allergic rhinitis by Chinese herbal medicine: A randomized placebo controlled trial
    Xue, CCL
    Thien, FCK
    Zhang, JJS
    Da Costa, C
    Li, CG
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2003, 9 (05) : 80 - 87
  • [10] Patient-Reported Clinical Characteristics in a Randomized Controlled Trial in Seasonal Allergic Rhinitis (SAR)
    Bernstein, Jonathan A.
    Ruiz, Nancy
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB219 - AB219